Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome

• Status: Completed
• Trial end date: 0000-00-00
• Target enrollment: 340
• Participant gender: Both

Summary

The main purpose of this study is to determine which is the best dose of a drug known as Dysport to give when treating one's type of upper back pain. The study will also examine the side effects of this treatment and its overall effect on one's disorder.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ipsen
• Treatments: abobotulinumtoxinA; Botulinum Toxins, Type A; incobotulinumtoxinA; onabotulinumtoxinA
• Last Updated: 2007-01-09

Criteria

Inclusion Criteria:

• Moderate-severe pain in upper back

• Myofascial pain syndrome for more than 6 months

• Active trigger points in upper back

Exclusion Criteria:

• Fibromyalgia and other non-myofascial pain conditions of upper back

• Duration of myofascial pain syndrome no longer than 24 months

• Steroid injections during previous 3 months

• Anaesthetic injection at trigger points during previous 1 month